Free tool
FAERS Monitor: Erythrocin
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050609 or its brand name (Erythrocin, Erythromycin Lactobionate). Reports on generic versions are filed under their own applications.
Reports
148
Serious
137
93% of reports
Hospitalization
56
Death reported
37
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- agranulocytosis19
- leukopenia19
- neutropenia16
- off label use14
- condition aggravated6
- diarrhoea6
- mixed liver injury6
- pneumonia6
- alanine aminotransferase increased5
- pyrexia5
- drug ineffective4
- hepatic function abnormal4
- nausea4
- pain4
- respiratory failure4
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2006 | 1 |
| 2007 | 6 |
| 2008 | 1 |
| 2009 | 11 |
| 2010 | 18 |
| 2011 | 18 |
| 2012 | 9 |
| 2013 | 5 |
| 2014 | 5 |
| 2015 | 1 |
| 2016 | 8 |
| 2017 | 3 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 2 |
| 2021 | 7 |
| 2022 | 19 |
| 2023 | 3 |
| 2024 | 7 |
| 2025 | 12 |
| 2026 | 2 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,011 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| mixed liver injurySignal | 6 | 283.9 | 129.6 | 1,418 |
| agranulocytosisSignal | 19 | 145.4 | 95.5 | 2,582 |
| leukopeniaSignal | 19 | 54.0 | 35.5 | 938 |
| neutropeniaSignal | 16 | 16.7 | 10.5 | 223 |
| hepatic function abnormalSignal | 4 | 15.2 | 5.8 | 40 |
| alanine aminotransferase increasedSignal | 5 | 11.6 | 4.9 | 38 |
| respiratory failureSignal | 4 | 7.8 | 3.0 | 17 |
| condition aggravatedSignal | 6 | 2.8 | 1.3 | 5 |
| pneumoniaSignal | 6 | 2.6 | 1.2 | 5 |
| off label useSignal | 14 | 2.3 | 1.4 | 9 |
| pyrexia | 5 | 2.1 | 0.9 | 2 |
| diarrhoea | 6 | 1.3 | 0.6 | 0 |
| pain | 4 | 0.9 | 0.4 | 0 |
| nausea | 4 | 0.7 | 0.3 | 0 |
| drug ineffective | 4 | 0.4 | 0.2 | 3 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.